Soquelitinib

DB18749InvestigationalSmall molecule

Soquelitinib: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase ITK/TSK
Curator reviewed
Formula / weight: C₂₅H₃₀N₄O₄S₂ · 514.66 g/mol (avg)
Also known as: Cyclopropanecarboxamide, N-[5-[[5-[[(3R)-hexahydro-3-methyl-4-(1-oxo-2-propen-1-yl)-1H-1,4-diazepin-1-yl]carbonyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]- · N-{5-[(5-{[(3R)-4-(prop-2-enoyl)-3-methyl-1,4-diazepan-1-yl]carbonyl}-4-methoxy-2-methylphenyl)sulfanyl]-1,3-thiazol-2-yl}cyclopropanecarboxamide
Code names: CP-000596 · CPI-000818 · CPI-596 · CPI-818

Resolves to

Compound

Structure

InChIKeyKNCWSXRTKLTULH-MRXNPFEDSA-NSMILESCOC1=CC(C)=C(SC2=CN=C(NC(=O)C3CC3)S2)C=C1C(=O)N1CCCN([C@H](C)C1)C(=O)C=C

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Soquelitinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.